Clinical Assessment: 30M — Palpitations (1 week), Right Hand Pain, Left Leg Chills/Shaking

Key Red Flag: Cardioembolic or Systemic Source

• Palpitations (likely arrhythmia)
• Right hand pain (possible arterial embolism or ischemia)
• Left leg chills/shaking (possible peripheral embolism, deep vein thrombosis, or neurological involvement)

Top Differential Diagnoses

Critical Questions to Ask

1. Fever, night sweats, weight loss? → IE, malignancy
2. IV drug use or recent dental/surgical procedure? → IE risk factors
3. Is the right hand pain cold, pale, or pulseless? → Acute limb ischemia (emergency)
4. Is the left leg shaking rhythmic (tremor) vs. involuntary shaking with cold feeling? → Rigor vs. neurological
5. History of DVT, miscarriages, clotting disorders? → Antiphospholipid syndrome
6. Recreational drugs (stimulants, cocaine)? → Arrhythmia + vasospasm
7. Family history of sudden cardiac death or arrhythmia? → Inherited channelopathy (Brugada, LQTS, ARVC)

Immediate Workup (Emergency Department)

• 12-lead ECG (AFib, WPW delta waves, QT prolongation, Brugada pattern)
• Continuous cardiac monitoring
• Echocardiogram (valvular vegetations, structural disease, thrombus)
• Troponin, BNP

• Peripheral pulses + capillary refill bilaterally
• Doppler ultrasound of upper extremity arteries
• If cold/pulseless → vascular surgery emergency

• Lower extremity Doppler (DVT vs. arterial insufficiency)
• Assess for signs of DVT (swelling, Homans), arterial occlusion (pallor, pain, paresthesia, paralysis, poikilothermia)

• Blood cultures x2 (before any antibiotics if IE suspected)
• CBC, CRP, ESR, procalcitonin
• BMP, LFTs, LDH

• PT/INR, aPTT
• Antiphospholipid antibodies (lupus anticoagulant, anti-cardiolipin, anti-β2GPI)
• ANA, ANCA if vasculitis suspected
• Hypercoagulable panel if thrombosis confirmed

Most Concerning Scenario

"Chills and shaking" in the context of palpitations and asymmetric limb symptoms = rule out infective endocarditis until proven otherwise.

• Arrhythmias (abscess extending to conduction system)
• Septic emboli to extremities (hand, leg)
• Rigors/fever (the "chills and shaking")

Bottom Line

Updated Clinical Reasoning

Pyelonephritis → Bacteremia → Cardiac valve seeding → Infective Endocarditis
                                                              ↓
                                          Septic emboli → Right hand (arterial occlusion/pain)
                                                        → Left leg (arterial occlusion/chills/rigors)

Critical New Considerations

• Many pyelonephritis cases involve transient bacteremia even when treated as outpatient
• Oral antibiotics may have suppressed but not eradicated a bacteremic source, especially if:
  • The causative organism had oral antibiotic resistance
  • Treatment was incomplete or adherence was poor
  • There was an underlying structural cardiac abnormality

• Rigors from ongoing/recurrent bacteremia rather than a local leg phenomenon
• Alternatively, a septic embolus to the left leg causing ischemia + systemic response

Revised Top Differential

Most Likely Organisms (GU source → IE)

Urgent Actions — This Patient Needs the ED Now

1. Blood cultures x2–3 (both sets before any antibiotic changes) — mandatory
2. Transthoracic echocardiogram (TTE) → if negative and suspicion remains, transesophageal echo (TEE)
3. 12-lead ECG + continuous monitoring — PR prolongation or new heart block suggests perivalvular abscess
4. Repeat urinalysis + urine culture — confirm eradication of original source
5. CBC, CMP, CRP, ESR, procalcitonin, LDH
6. Doppler ultrasound of right upper and left lower extremities — assess for arterial occlusion from septic emboli
7. Review the antibiotic used for pyelo — organism, susceptibilities, whether adequate coverage was achieved

Bottom Line

Treatment Plan — Presumed Subacute IE with Septic Emboli

Phase 1: Emergency Department — First 2–6 Hours

Step 1 — Cultures First

• Blood cultures x3 sets from separate venipuncture sites, 30–60 min apart if stable
• Urine culture
• If hemodynamically unstable → draw 2 sets simultaneously and start antibiotics immediately

Step 2 — Stabilization & Monitoring

• IV access x2 large-bore
• Continuous cardiac monitoring (telemetry)
• 12-lead ECG — look for new AV block (suggests perivalvular abscess → surgical emergency)
• Oxygen if SpO₂ < 94%
• NPO if surgical candidacy is possible

Step 3 — Urgent Imaging

Phase 2 — Empirical Antibiotic Therapy

Native Valve, Community-Acquired (GU source suspected):

Enterococcus from GU source is the primary target — ampicillin-based regimen is preferred if susceptible. AHA guidelines recommend 4–6 weeks of bactericidal IV antibiotics for native valve IE.

Phase 3 — Targeted Therapy (After Culture Results)

Phase 4 — Embolic Limb Management

• Assess the 6 P's: Pain, Pallor, Pulselessness, Paresthesia, Paralysis, Poikilothermia
• If signs of acute limb ischemia → emergent vascular surgery consultation
• Embolectomy or catheter-directed thrombolysis may be required
• Anticoagulation is controversial in IE — septic emboli risk fragmentation; discuss with vascular surgery + ID team

• If DVT confirmed → anticoagulation (LMWH bridge to warfarin or DOAC)
• If arterial embolus → vascular surgery
• If rigors only (no vascular occlusion) → systemic sepsis management

Phase 5 — Surgical Indications (Involve Cardiothoracic Surgery Early)

Phase 6 — Source Control

• Repeat urine culture — confirm pyelonephritis eradicated
• Renal ultrasound or CT — rule out renal abscess or obstructive uropathy as ongoing nidus
• If renal abscess present → drainage required before IE can be cured
• Dental evaluation — rule out concurrent oral source

Consultations Required

Monitoring During Treatment

• Blood cultures every 48h until clearance confirmed
• ECG daily (watch for AV block → abscess)
• Repeat TTE/TEE at 1–2 weeks to assess vegetation response
• Renal function + vancomycin/gentamicin levels every 48–72h
• CRP/ESR weekly as treatment response markers

Key Principle

This patient requires IV antibiotics for 4–6 weeks, likely inpatient for the first 2 weeks minimum, with close multidisciplinary oversight. Oral step-down (per recent POET trial data) may be considered in select stable patients after bacteremia clearance — but only under ID guidance.